贊宇科技(002637.SZ):目前磺化表面活性劑年產能突破110萬噸
格隆匯12月21日丨贊宇科技(002637.SZ)在投資者關係活動上表示,公司是專業從事表面活性劑、油脂化學品研發製造和洗護用品代加工的高新技術企業,表面活性劑和油脂化學品的市場佔有率均約三分之一,是國內研究和生產表面活性劑、油脂化學品的龍頭企業之一。公司在杭州錢塘區、浙江嘉興、江蘇鎮江、四川眉山、河南鶴壁、廣東江門、印尼雅加達等地建有工業化生產基地,目前磺化表面活性劑年產能突破110萬噸、油脂化學品年產能突破100萬噸。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.